سعر فراكسيبارين 0.6 مل 10 حقن مملوءة مسبقاً 2022

Nadroparin calcium (low-molecular-weight heparin) injection in 0.6 ml prefilled syringes, pack of 10; an anticoagulant used to prevent and treat thromboembolic disorders.

• Prophylaxis of thromboembolic disorders associated with general and orthopedic surgery (particularly deep vein thrombosis and pulmonary embolism).Population: AdultsHealth Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Prophylaxis of thromboembolic disorders in high-risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) immobilised due to acute illness or hospitalised in an intensive care unit.Population: AdultsHealth Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Treatment of deep vein thrombosis.Population: AdultsHealth Canada Drug Product Database (Aspen Pharmacare Canada Inc)

• Haemorrhagic manifestations at various sites are very common; small injection-site haematomas are very common (sometimes with firm nodules that resolve within days); major haemorrhage, including retroperitoneal or intracranial bleeding, has been reported, in some cases fatal.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Transient elevation of liver transaminases (AST, ALT) is common. Rare: thrombocytopenia (including heparin-induced), thrombocytosis, rash, allergic reactions, injection-site calcinosis and skin necrosis. Very rare: eosinophilia, priapism, angioedema/anaphylactoid reactions; reversible hypoaldosteronism with hyperkalaemia; osteopenia with prolonged use.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)

• Hypersensitivity to nadroparin or any constituent, or to other low-molecular-weight heparins and/or heparin; history of confirmed or suspected immunologically mediated heparin-induced thrombocytopenia, or a positive in-vitro platelet-aggregation test with nadroparin.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Acute infective endocarditis; active bleeding or increased risk of haemorrhage related to haemostasis disorders, major clotting disorders or generalised haemorrhagic tendency; organic lesions likely to bleed (e.g. active peptic ulcer); haemorrhagic cerebrovascular event; severe uncontrolled hypertension; diabetic or haemorrhagic retinopathy; injuries to or operations on the central nervous system, eyes and ears.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Spinal/epidural anaesthesia where repeated high (treatment) doses are required; severe renal insufficiency (creatinine clearance below 30 mL/min) in patients treated for thromboembolic disorders, unstable angina or non-Q wave myocardial infarction.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)

• Must never be administered intramuscularly. Cannot be used interchangeably (unit for unit) with unfractionated heparin or other low-molecular-weight heparins; care is needed to use the correct formulation (9,500 or 19,000 anti-Xa IU/mL).International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Bleeding can occur at any site; use with extreme caution in patients at increased risk of haemorrhage. An unexpected fall in haematocrit or blood pressure should prompt a search for a bleeding site. Elderly patients, patients with renal or hepatic insufficiency and extremes of body weight are at higher risk.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Heparin-induced thrombocytopenia, occasionally severe and associated with arterial or venous thrombosis, has been reported; treatment must be discontinued if it is suspected (e.g. platelet fall of 30-50% from baseline or new/worsening thrombosis).International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)

• Oral anticoagulants, systemic glucocorticoids, dextrans, platelet inhibitors, thrombolytic agentsUse nadroparin with caution in patients receiving these agents (increased bleeding risk).Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Aspirin, other salicylates, NSAIDs, antiplatelet agentsConcomitant use is not recommended in the prophylaxis or treatment of venous thromboembolism or prevention of clotting in haemodialysis because of increased bleeding risk; if unavoidable, careful clinical and laboratory monitoring is needed. Aspirin up to 325 mg/day is used with nadroparin in unstable angina/non-Q wave MI.Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• Drugs that may cause hyperkalaemia (e.g. ACE inhibitors, NSAIDs)Heparin-induced hypoaldosteronism may add to the risk of hyperkalaemia; monitor plasma potassium in patients at risk.Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)

• Limited clinical data on transplacental passage; as with other low-molecular-weight heparins, nadroparin should not be used in pregnancy unless the benefits outweigh the risks. Congenital anomalies and fetal deaths have been reported with LMWHs in pregnancy without established causality; pregnant women are at increased risk of bleeding and must be monitored; pregnant women with prosthetic heart valves are at very high thromboembolic risk.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)
• It is not known whether nadroparin is excreted in human milk; use during breast-feeding is not advised.International label, equivalent formulation · Health Canada Drug Product Database (Aspen Pharmacare Canada Inc)

• Nadroparin calcium: Low-molecular-weight heparin obtained by depolymerisation of porcine mucosal heparin (mean MW about 4,300 Da); binds antithrombin III through a specific pentasaccharide and accelerates inhibition of factor Xa, which accounts for most of its antithrombotic effect.